BRAF and melanoma: Follow-up scans were absent due to rapid clinical deterioration after progression under targeted therapy with BRAF and/or MEK inhibitors (N = 5), due to clinical deterioration in patients with preexisting aggressive disease (N = 5), due to treatment cessation because of cerebral hemorrhage which is common in patients with melanoma brain metastases (N = 5), and due to a patient refusing further radiological evaluation because of claustrophobia (N = 1) (Fig. 1).